Arbutus Biopharma Corporation ABUS Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's operating lease liabilities (current)?
- Arbutus Biopharma Corporation (ABUS) reported operating lease liabilities (current) of $631K in Q1 2026.
- How has Arbutus Biopharma Corporation's operating lease liabilities (current) changed year-over-year?
- Arbutus Biopharma Corporation's operating lease liabilities (current) increased by 12.1% year-over-year, from $563K to $631K.
- What is the long-term trend for Arbutus Biopharma Corporation's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's operating lease liabilities (current) has grown at a 7.0% compound annual growth rate (CAGR), from $390K to $547K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.